Navigation Links
River Vision Announces Completion of $17 million Series A Financing
Date:12/12/2012

NEW YORK, Dec. 12, 2012 /PRNewswire-iReach/ -- River Vision Development Corp. today announced the completion of a Series A financing, raising $17 million for the development of a novel protein therapy, RV 001, for the treatment of Graves' Orbitopathy (GO). 

GO is a condition afflicting a proportion of Graves' Disease patients, in which an autoimmune response is mounted against tissues behind the eye, causing inflammation, tissue proliferation and excess production of extracellular matrix.  The resulting excess tissue in the area behind the eye causes the eyeballs to protrude from the socket, resulting in often serious ocular morbidity and significant changes in the patient's appearance.

The Series A financing was led by SR One and Lundbeckfond Ventures with participation from Narrow River Management.  As a result of the financing, Brian M. Gallagher, Jr., Ph.D. a partner at SR One and Johan Kördel, Ph.D. a senior partner at Lundbeckfonden have joined River Vision's Board of Directors. "We are delighted to be working with SR One and Lundbeckfonden on this exciting project," said Dave Madden, CEO of River Vision.  "They bring a wealth of experience and relationships that should be invaluable to River Vision as we bring RV001 forward through development."

"The experience of the management team, the quality of the science behind the hypothesis and unmet medical need in GO combine to make this a very promising rare disease product opportunity" remarked Dr. Gallagher.  "We are pleased to collaborate with SR One and the River Vision management team on this exciting project" added Dr. Kördel "and believe the planned study will give us an excellent read on the potential of RV001 to treat this serious autoimmune condition."

About River Vision Development Corp.

River Vision Development Corp. was founded by Narrow River Management, LP (Narrow River) for the sole purpose of developing RV001 for GO and other potential indications.  The Company is managed under contract with Narrow River, which founds and provides leadership expertise for special purpose drug development companies. 

About SR One

SR One is the independent corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested approximately $700 million in more than 140 companies, and its current portfolio includes over 30 private and public companies. For more information, visit www.srone.com.

About Lundbeckfond Ventures

Lundbeckfond Ventures is an evergreen life science venture fund established and wholly owned by the Lundbeck Foundation. The firm is investing internationally with focus on life science companies that address areas with real unmet medical needs. On an annual basis, Lundbeckfond Ventures invests up to € 50 million. For more information, visit www.lundbeckfondventures.dk

Media Contact: Dave Madden River Vision Development Corp., (212) 582-8400 x105, dmadden@narrowrivermgmt.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE River Vision Development Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. First Paralyzed Formula Race Car Drivers "Road to Indy" Sponsored By Coloplast
2. Safe Driving Prescription for Senior Drivers
3. Nedbank Golf Challenge a Driver for Breast Cancer in South Africa
4. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
5. MediPendant™ to Return to Television on May 20th New Television Campaign - Company Provides MediPendant™ Update
6. Rural Health-Systems Benefit From Remote Pharmacy Technician Supervision
7. Medical Alarm Begins Revenue Recognition from Largest Set of Orders -- Releases New Television Commercial
8. Ted Pacha Joins Pinnaclife as President of its Healthcare Distribution Division
9. DataMotion Files Provisional Patent for Technology that Enables Easy and Secure Doctor-Patient Email Interaction
10. Spot Vision Screener wins Bronze in International Design Excellence Awards
11. Transitions Optical Brings Importance Of Healthy, Enhanced Vision Into Focus By Taking National Sightseeing City Tour To Chicago And Announcing The Citys Top 10 Sights To See
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ZIONA, Israel , May 4, ... TASE: BVXV) announced today that BiondVax,s CEO, Dr. Ron ... conference in New York City . ... at 10:30am at Pioneers 2016, a conference presented by ... York Palace Hotel. The BiondVax presentation that Dr. ...
(Date:5/4/2016)... May 4, 2016 Yissum ... announced today that it had signed an exclusive ... , developer of novel protein degradation and immunomodulatory drugs ... commercialization of drug candidates representing first-in-class therapy for hematologic ... not disclosed. The novel technology was developed ...
(Date:5/4/2016)... , May 4, 2016 ... completion of an alternative public offering (APO). This was ... operating company, Valeritas, Inc. and a private placement of ... at $5.00 per share. Under the terms ... 3, 2016, Valeritas Holdings, Inc. will trade on the ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... In ... career-focused education and corporate training, and the National Military Family Association, a nonprofit ... Aquino as the second full-tuition scholarship recipient of 2016. , “Being awarded ...
(Date:5/6/2016)... ... May 06, 2016 , ... “ Crossing Over: Affirmations of Faith in ... patients who have allowed those holding vigil to glimpse into the supernatural as their ... to help readers spiritually and practically gain insight into providing care to terminal patients. ...
(Date:5/5/2016)... ... ... While the practice and profession of Aging Life Care is not new, there ... and resources. Aging Life Care plays an important role as these professionals are prepared ... Care is a holistic, client-centered approach to caring for older adults or others facing ...
(Date:5/5/2016)... ... , ... Textile Exchange is excited to announce the release of ... stakeholder review is an important opportunity for interested parties to give input into the ... wool industry., The RWS is intended to be a global benchmark for animal welfare ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... to offer patients with non-valvular atrial fibrillation (A-Fib) an alternative to long-term warfarin ... first offering the procedure in April of 2015, Florida Hospital Pepin Heart Institute ...
Breaking Medicine News(10 mins):